Your patients leave the clinic and disappear into a monitoring void. Half will relapse within 6–12 months. Most of those relapses will go undetected until it's too late to intervene easily.
PHQ-9 by email gets 30–40% completion in most practices. That sounds like a patient engagement problem. It's actually a monitoring architecture problem.
When a clinician proposes EmoDTx and installs it with the patient during the visit, 80% of patients activate within 48 hours. When the request comes by email, the rate drops to 30–40%. The difference is one conversation.
Digital phenotyping sounds like something from a research conference. It's actually a simple idea: use the sensors in your patient's pocket to measure what depression does to behavior.
$50 per patient per month sounds expensive — until you compare it to the revenue leaking out of your TMS and Spravato programs every year. Here is how a CFO should translate the clinical reality their medical director already knows into a financial case.
You monitor patients for 2 hours post-administration under REMS. What happens in the other 166 hours of the week is largely invisible — and that's where response durability is determined.
Every C-suite meeting surfaces the same malpractice scenario within 30 minutes. Here is why Emobot's design makes it structurally impossible — the AI analyzes how the voice sounds, never what is said, with zero content ever leaving the patient's phone.
Every previous generation of digital health required patient effort — and every one of them needed workflow integration to compensate for the adherence problem that followed. Passive monitoring removes the first link in that chain, and the whole chain collapses.